Xencor, Inc. - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Xencor, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Xencor, Inc. - Product Pipeline Review - 2016', provides an overview of the Xencor, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Xencor, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Xencor, Inc.
- The report provides overview of Xencor, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Xencor, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Xencor, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Xencor, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Xencor, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Xencor, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Xencor, Inc. Snapshot 6
Xencor, Inc. Overview 6
Key Information 6
Key Facts 6
Xencor, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Xencor, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Xencor, Inc. - Pipeline Products Glance 16
Xencor, Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Xencor, Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Xencor, Inc. - Drug Profiles 20
XmAb-5871 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibody 1 for Oncology 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody 2 for Oncology 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
XmAb-7195 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
XENP-1138 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
XmAb-13676 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
XmAb-13677 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
XmAb-14045 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
XmAb-14484 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
XmAb-18087 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
XmAb-19722 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
XmAb-20717 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
XmAb-6755 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody to Agonize CD32b for Immunology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody to Agonize CD32b for Undisclosed Indication 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Xencor, Inc. - Pipeline Analysis 36
Xencor, Inc. - Pipeline Products by Target 36
Xencor, Inc. - Pipeline Products by Route of Administration 38
Xencor, Inc. - Pipeline Products by Molecule Type 39
Xencor, Inc. - Pipeline Products by Mechanism of Action 40
Xencor, Inc. - Recent Pipeline Updates 41
Xencor, Inc. - Dormant Projects 45
Xencor, Inc. - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Xencor, Inc., Key Information 6
Xencor, Inc., Key Facts 6
Xencor, Inc. - Pipeline by Indication, 2016 8
Xencor, Inc. - Pipeline by Stage of Development, 2016 10
Xencor, Inc. - Monotherapy Products in Pipeline, 2016 11
Xencor, Inc. - Partnered Products in Pipeline, 2016 12
Xencor, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13
Xencor, Inc. - Out-Licensed Products in Pipeline, 2016 14
Xencor, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
Xencor, Inc. - Phase II, 2016 16
Xencor, Inc. - Phase I, 2016 17
Xencor, Inc. - Preclinical, 2016 18
Xencor, Inc. - Discovery, 2016 19
Xencor, Inc. - Pipeline by Target, 2016 37
Xencor, Inc. - Pipeline by Route of Administration, 2016 38
Xencor, Inc. - Pipeline by Molecule Type, 2016 39
Xencor, Inc. - Pipeline Products by Mechanism of Action, 2016 40
Xencor, Inc. - Recent Pipeline Updates, 2016 41
Xencor, Inc. - Dormant Developmental Projects,2016 45
Xencor, Inc., Other Locations 46